GlassScriptPhysician profile
Phillip G Walker
NPI 1881060754
$13,944.83
in general payments reported to CMS, 2019-2025
27 companies · $2,966 in 2025
The $2,966 reported for 2025 was more than what 96% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,474 · 2022: $2,642 · 2023: $3,311 · 2024: $2,552 · 2025: $2,966.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,829.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,828.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,531.40 | 2021-2025 | |
| Otsuka America Pharmaceutical, INC. | $1,185.93 | 2021-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,165.02 | 2021-2025 | Caplyta |
| Alkermes, INC. | $1,119.75 | 2021-2025 | Lybalvi, Aristada, Vivitrol |
| Corium, LLC | $1,048.66 | 2021-2025 | Azstarys |
| Axsome Therapeutics, INC. | $911.49 | 2023-2025 | Auvelity |
| Neurocrine Biosciences, INC. | $911.41 | 2021-2025 | Ingrezza |
| Teva Pharmaceuticals USA, INC. | $844.34 | 2021-2025 | Austedo Xr, Uzedy, Austedo Xr |
| Janssen Pharmaceuticals, INC | $842.70 | 2021-2025 | Spravato, Invega Sustenna, Invega Trinza |
| Lundbeck LLC | $794.58 | 2021-2025 | Abilify Maintena, Rexulti, Abilify Asimtufii |
| Sunovion Pharmaceuticals INC. | $723.29 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $591.63 | 2021-2025 | Trintellix |
| Supernus Pharmaceuticals, INC. | $488.76 | 2021-2025 | Qelbree, Qelbree |
| Vanda Pharmaceuticals INC. | $462.75 | 2021-2025 | Fanapt, Hetlioz |
| Tris Pharma INC | $246.11 | 2023-2024 | Dyanavel Xr |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironshore Pharmaceuticals INC. | $229.28 | 2022-2024 | Jornay Pm |
| Almatica Pharma LLC | $221.39 | 2022-2025 | Loreev Xr, Sertraline Hcl, Citalopram |
| E.R. Squibb & Sons, L.L.C. | $201.47 | 2024-2025 | Cobenfy |
| Adlon Therapeutics L.P. | $154.20 | 2021 | |
| Bausch Health US, LLC | $98.78 | 2021-2023 | Wellbutrin, Aplenzin |
| Biogen, INC. | $38.08 | 2024 | |
| Idorsia Pharmaceuticals US INC | $35.17 | 2023-2024 | Quviviq |
| Neuronetics, INC. | $32.07 | 2021-2022 | |
| Sage Therapeutics, LLC | $21.32 | 2022 | |
| Acadia Pharmaceuticals INC | $18.94 | 2021 | |
| Collegium Pharmaceutical, INC. | $13.46 | 2025 | Jornay Pm |
| Alfasigma USA, INC. | $12.85 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Phillip Walker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.